Aryl Piperidine MGL Modulators for Targeted Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with monoacylglycerol lipase (MGL) modulation, such as pain, psychiatric disorders, and cancer, often have limited efficacy and are plagued by side effects due to non-specific action on the cannabinoid system, and there is a need for more targeted therapeutic approaches that minimize these issues.
Innovation Solution
Development of specific chemical entities and pharmaceutical compositions that modulate MGL activity, including inhibitors, to target MGL receptors in a more precise manner, thereby potentiating the cannabinoid system and reducing side effects by increasing 2-AG levels in specific brain regions, thereby treating a range of conditions including pain, psychiatric disorders, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional CB1 agonists are used to treat diseases associated with MGL modulation, then therapeutic effects are achieved, but side effects occur due to non-specific action on the cannabinoid system
Solution Approach 1:
The patent applies local quality by developing MGL-specific modulators that selectively target the monoacylglycerol lipase enzyme in specific brain regions (such as the striatum and hippocampus) rather than acting broadly on the cannabinoid system. This selective targeting achieves therapeutic effects in pain, psychiatric disorders, and cancer while minimizing non-specific side effects associated with CB1 agonists.
Solution Approach 2:
The patent uses MGL modulators as intermediary substances that indirectly potentiate the cannabinoid system by increasing 2-AG levels. Instead of directly activating CB1 receptors, these modulators work through MGL inhibition to elevate endocannabinoid concentrations, providing a more precise and safer therapeutic approach.
2Adaptability or versatility
If non-specific action on the cannabinoid system is used, then broad therapeutic coverage is achieved, but precision and specificity are reduced
Solution Approach 1:
The patent applies parameter changes by modifying the molecular target from CB1 receptors to MGL enzyme. This parameter change enables selective modulation of 2-AG metabolism in specific brain regions, achieving both broad therapeutic coverage across multiple conditions and high precision in target engagement through MGL-specific binding.
3Reliability
If MGL modulation is used to increase 2-AG levels, then therapeutic effects are enhanced, but complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts the MGL modulation mechanism from the broader cannabinoid system, isolating a specific enzymatic target that can be independently and precisely controlled. This extraction simplifies the therapeutic approach by focusing on a single enzyme pathway rather than the complex multi-receptor cannabinoid system, while maintaining enhanced therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MGL modulators effectively treat various conditions by enhancing 2-AG levels in specific brain regions, reducing pain, improving psychiatric disorders, and inhibiting cancer progression with minimal side effects compared to traditional CB1 agonists.
Implementation Method 1
Monoacylglycerol lipase (MGL), also known as MAG lipase and MGL, is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol in the central nervous system
Data Source
AI summary
Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions:wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.